Drug intelligence / Profile preview

rifampin + isoniazid + pyrazinamide + ethambutol followed by rifampin + isoniazid

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A standardized tuberculosis (TB) treatment regimen consisting of two phases: an intensive phase using four drugs (rifampin, isoniazid, pyrazinamide, and ethambutol) for 2 months, followed by a continuation phase using two drugs (rifampin and isoniazid) for 4-7 months. This regimen is the preferred treatment for drug-susceptible pulmonary tuberculosis.

Brand names: Rifater followed by Rifamate
Other names: RIPE followed by RIRIP followed by RI

Targets

InhAPncA (Nicotinamidase)rpoB (DNA-directed RNA polymerase subunit beta)EmbC (Mycobacterium avium complex arabinosyltransferase EmbC)

Beyond the preview

Go deeper on rifampin + isoniazid + pyrazinamide + ethambutol followed by rifampin + isoniazid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rifampin + isoniazid + pyrazinamide + ethambutol followed by rifampin + isoniazid.

Explore the full profile